GE HealthCare Korea announced the signing of a Memorandum of Understanding (MOU) with Supernova Bio, a Korean research and development company specializing in medical nanoparticles, to collaborate on the development of next-generation aesthetic and cosmetic treatments.
According to GE HealthCare, Supernova Bio has expertise in multifunctional polymer materials and has developed a nanoparticle drug delivery platform that can be used to diagnose and treat various diseases.
Notably, the company has demonstrated the efficacy of its localized fat-dissolving agent in mouse trials.
Under the terms of the MOU, Supernova Bio will provide the necessary technical support, solutions, and procedures for the market development of next-generation aesthetic treatments. In turn, GE HealthCare will offer technological support through its ultrasound diagnostic medical devices.
Both companies are particularly focused on pioneering the next-generation aesthetic treatment market using Supernova Bio’s localized fat-dissolving agent and GE Healthcare’s ultrasound diagnostic solutions.
“The demand in the aesthetic and cosmetic medical market, including obesity treatments, is continuously increasing,” GE HealthCare Korea CEO Kim Yong-duk said. “This collaboration with Supernova Bio reflects this growing demand and is part of our strategy to provide medical technologies that support a better quality of life.”
GE HealthCare will continue its efforts to deliver superior treatment outcomes with its leading med-tech solutions, Kim added.
Supernova CEO Yim Hyung-woo also said, “We are delighted to collaborate with GE HealthCare, a global leader, on developing next-generation aesthetic treatment solutions.”
By combining the company’s fat-dissolving technology with GE HealthCare’s medical devices, we expect to achieve more efficient treatments, Yim added.